Double-blind Placebo-controlled Trial of Fluoxetine in Adolescents with Comorbid Major Depression and an Alcohol Use Disorder

Overview

Journal Addict Behav

Specialties Psychiatry
Social Sciences

Date 2009 Mar 27

PMID 19321268

Citations 36

Authors

Jack R Cornelius

Oscar G Bukstein

D Scott Wood

Levent Kirisci

Antoine Douaihy

Duncan B Clark

Affiliations

Soon will be listed here.

Abstract

Objective: This study compared the acute phase (12-week) efficacy of fluoxetine versus placebo for the treatment of the depressive symptoms and the drinking of adolescents with comorbid major depression (MDD) and an alcohol use disorder (AUD). We hypothesized that fluoxetine would demonstrate efficacy versus placebo for the treatment of both the depressive symptoms and the drinking of comorbid MDD/AUD adolescents.

Methods: We conducted the first double-blind placebo-controlled study of fluoxetine in adolescents with comorbid MDD/AUD. All participants in both treatment groups also received intensive manual-based Cognitive Behavioral Therapy (CBT) and Motivation Enhancement Therapy (MET).

Results: Fluoxetine was well tolerated in this treatment population. No significant group-by-time interactions were noted for any depression-related or drinking-related outcome variable. Subjects in both the fluoxetine group and the placebo group showed significant within-group improvement in both depressive symptoms and level of alcohol consumption. End-of-study levels of depression and drinking were low in both treatment groups.

Conclusions: The lack of a significant between-group difference in depressive symptoms and in drinking may reflect limited medication efficacy, or may result from limited sample size or from efficacy of the CBT/MET psychotherapy. Large multi-site studies are warranted to further clarify the efficacy of SSRI medications in this adolescent MDD/AUD population.

Citing Articles

A sex- and gender-based analysis of alcohol treatment intervention research involving youth: A methodological systematic review.

Lowik A, Mniszak C, Pang M, Ziafat K, Karamouzian M, Knight R PLoS Med. 2024; 21(6):e1004413.

PMID: 38829916 PMC: 11182506. DOI: 10.1371/journal.pmed.1004413.

Bahji A, Danilewitz M, Sloan M, Tang V, Crockford D CMAJ. 2024; 196(19):E685-E686.

PMID: 38772607 PMC: 11104573. DOI: 10.1503/cmaj.149917-l-f.

Concerns regarding the recommendation against prescribing selective serotonin reuptake inhibitors in the Canadian guideline for the clinical management of high-risk drinking and alcohol use disorder.

Bahji A, Danilewitz M, Sloan M, Tang V, Crockford D CMAJ. 2024; 196(10):E346-E347.

PMID: 38499302 PMC: 10948180. DOI: 10.1503/cmaj.149917-l.

Components of Outpatient Child and Youth Concurrent Disorders Programs: A Critical Interpretive Synthesis: Composantes des programmes de troubles concomitants des enfants et des jeunes ambulatoires : une synthèse interprétative critique.

Rosic T, Lovell E, MacMillan H, Samaan Z, Morgan R Can J Psychiatry. 2023; 69(6):381-394.

PMID: 37941334 PMC: 11107442. DOI: 10.1177/07067437231212037.

Selective serotonin reuptake inhibitors in the treatment of depression, anxiety, and post-traumatic stress disorder in substance use disorders: a Bayesian meta-analysis.

Fluyau D, Mitra P, Jain A, Kailasam V, Pierre C Eur J Clin Pharmacol. 2022; 78(6):931-942.

PMID: 35246699 DOI: 10.1007/s00228-022-03303-4.

References

Kaufman J, Birmaher B, Brent D, Rao U, Flynn C, Moreci P . Schedule for Affective Disorders and Schizophrenia for School-Age Children-Present and Lifetime Version (K-SADS-PL): initial reliability and validity data. J Am Acad Child Adolesc Psychiatry. 1997; 36(7):980-8. DOI: 10.1097/00004583-199707000-00021. View

March J, Silva S, Compton S, Anthony G, DeVeaugh-Geiss J, Califf R . The Child and Adolescent Psychiatry Trials Network (CAPTN). J Am Acad Child Adolesc Psychiatry. 2004; 43(5):515-8. DOI: 10.1097/00004583-200405000-00004. View

Blazer D, Kessler R, McGonagle K, Swartz M . The prevalence and distribution of major depression in a national community sample: the National Comorbidity Survey. Am J Psychiatry. 1994; 151(7):979-86. DOI: 10.1176/ajp.151.7.979. View

Brent D, Holder D, Kolko D, Birmaher B, Baugher M, Roth C . A clinical psychotherapy trial for adolescent depression comparing cognitive, family, and supportive therapy. Arch Gen Psychiatry. 1997; 54(9):877-85. DOI: 10.1001/archpsyc.1997.01830210125017. View

. Biological factors in prepubertal major depression. Pediatr Ann. 1986; 15(12):867, 870-2, 873-4. DOI: 10.3928/0090-4481-19861201-09. View

Sobell L, Sobell M, Leo G, Cancilla A . Reliability of a timeline method: assessing normal drinkers' reports of recent drinking and a comparative evaluation across several populations. Br J Addict. 1988; 83(4):393-402. DOI: 10.1111/j.1360-0443.1988.tb00485.x. View

Cornelius J, Bukstein O, Birmaher B, Salloum I, Lynch K, Pollock N . Fluoxetine in adolescents with major depression and an alcohol use disorder: an open-label trial. Addict Behav. 2001; 26(5):735-9. DOI: 10.1016/s0306-4603(00)00152-0. View

Birmaher B, Brent D, Kolko D, Baugher M, Bridge J, Holder D . Clinical outcome after short-term psychotherapy for adolescents with major depressive disorder. Arch Gen Psychiatry. 2000; 57(1):29-36. DOI: 10.1001/archpsyc.57.1.29. View

Cornelius J, Clark D, Bukstein O, Birmaher B, Salloum I, Brown S . Acute phase and five-year follow-up study of fluoxetine in adolescents with major depression and a comorbid substance use disorder: a review. Addict Behav. 2005; 30(9):1824-33. DOI: 10.1016/j.addbeh.2005.07.007. View

10.

Riggs P, Mikulich-Gilbertson S, Davies R, Lohman M, Klein C, Stover S . A randomized controlled trial of fluoxetine and cognitive behavioral therapy in adolescents with major depression, behavior problems, and substance use disorders. Arch Pediatr Adolesc Med. 2007; 161(11):1026-34. DOI: 10.1001/archpedi.161.11.1026. View

11.

Emslie G, Heiligenstein J, Wagner K, Hoog S, Ernest D, Brown E . Fluoxetine for acute treatment of depression in children and adolescents: a placebo-controlled, randomized clinical trial. J Am Acad Child Adolesc Psychiatry. 2002; 41(10):1205-15. DOI: 10.1097/00004583-200210000-00010. View

12.

Young S, Corley R, Stallings M, Rhee S, Crowley T, Hewitt J . Substance use, abuse and dependence in adolescence: prevalence, symptom profiles and correlates. Drug Alcohol Depend. 2002; 68(3):309-22. DOI: 10.1016/s0376-8716(02)00225-9. View

13.

Martin C, Pollock N, Bukstein O, Lynch K . Inter-rater reliability of the SCID alcohol and substance use disorders section among adolescents. Drug Alcohol Depend. 2000; 59(2):173-6. DOI: 10.1016/s0376-8716(99)00119-2. View

14.

Jain U, Birmaher B, Garcia M, Al-Shabbout M, Ryan N . Fluoxetine in children and adolescents with mood disorders: a chart review of efficacy and adverse effects. J Child Adolesc Psychopharmacol. 2009; 2(4):259-65. DOI: 10.1089/cap.1992.2.259. View

15.

Beck A, Ward C, Mendelson M, Mock J, ERBAUGH J . An inventory for measuring depression. Arch Gen Psychiatry. 1961; 4:561-71. DOI: 10.1001/archpsyc.1961.01710120031004. View

16.

Nunes E, Levin F . Treatment of depression in patients with alcohol or other drug dependence: a meta-analysis. JAMA. 2004; 291(15):1887-96. DOI: 10.1001/jama.291.15.1887. View

17.

Rohde P, Lewinsohn P, Seeley J . Comorbidity of unipolar depression: II. Comorbidity with other mental disorders in adolescents and adults. J Abnorm Psychol. 1991; 100(2):214-22. View

18.

Emslie G, Rush A, Weinberg W, Kowatch R, Hughes C, Carmody T . A double-blind, randomized, placebo-controlled trial of fluoxetine in children and adolescents with depression. Arch Gen Psychiatry. 1997; 54(11):1031-7. DOI: 10.1001/archpsyc.1997.01830230069010. View

19.

Cornelius J, Bukstein O, Salloum I, Kelly T, Scott Wood D, Clark D . Fluoxetine in depressed AUD adolescents: a 1-year follow-up evaluation. J Child Adolesc Psychopharmacol. 2004; 14(1):33-8. DOI: 10.1089/104454604773840463. View

20.

Klein R, Mannuzza S, Koplewicz H, Tancer N, Shah M, Liang V . Adolescent depression: controlled desipramine treatment and atypical features. Depress Anxiety. 1998; 7(1):15-31. DOI: 10.1002/(sici)1520-6394(1998)7:1<15::aid-da3>3.0.co;2-4. View